Research Topics
Genomes and GenesSpecies | Paul RidkerSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trialPaul M Ridker
MPH, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Ave East, Boston, MA 02215 1204, USA
Circulation 126:2739-48. 2012....- Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?Paul M Ridker
Center for Cardiovascular Disease Prevention and the Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Curr Atheroscler Rep 15:295. 2013..Together, CANTOS and CIRT represent a core test of the inflammation hypothesis of atherothrombosis and the exploration of a potential new phase for cardiovascular therapeutics... - Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trialPaul M Ridker
Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Lancet 380:565-71. 2012..We undertook an analysis of participants from the JUPITER trial to address the balance of vascular benefits and diabetes hazard of statin use... 
Cardiovascular inflammation in healthy women: multilevel associations with state-level prosperity, productivity and income inequalityCHERYL R CLARK
Division of General Medicine and Primary Care, Brigham and Women s Faulkner Hospitalist Program, Harvard Medical School, Boston, Massachusetts, USA
BMC Public Health 12:211. 2012....- Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trialPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA 02215, USA
Clin Chem 58:877-86. 2012..Whether measures of Lp-PLA(2) mass or activity continue to predict risk after LDL-C reduction by statin therapy is uncertain... - An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validationChristopher S Coffey
Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294 0022, USA
BMC Bioinformatics 5:49. 2004..One advantage of the MDR method is that it provides an internal prediction error for validation. We summarize our use of this internal prediction error for model validation... 
High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary preventionPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
Am J Cardiol 92:17K-22K. 2003....- C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for menPaul M Ridker
Donald W Reynolds Center for Cardiovascular Research, Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Circulation 118:2243-51, 4p following 2251. 2008.... - Established and emerging plasma biomarkers in the prediction of first atherothrombotic eventsPaul M Ridker
Center for Cardiovascular Disease Prevention and the Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, Mass 02115, USA
Circulation 109:IV6-19. 2004 - Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yesP M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
J Thromb Haemost 2:1034-7. 2004 - High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefitPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, Mass 02215, USA
Am Heart J 148:S19-26. 2004..Inclusion of hs-CRP measurement in risk screening and use of this information to guide preventive therapy could result in a marked improvement in prevention of cardiovascular morbidity and mortality... - Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?Paul M Ridker
Donald W Reynolds Center for Cardiovascular Research, Boston, Mass, USA
Circulation 109:2818-25. 2004..Toward this end, we believe experts in the fields of epidemiology, prevention, vascular biology, and clinical cardiology should be convened to begin discussing the merits of this proposal... - Rosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
N Engl J Med 359:2195-207. 2008.... - Moving toward new statin guidelines in a post-JUPITER world: principles to considerPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA 02215, USA
Curr Atheroscler Rep 11:249-56. 2009..Although lifestyle interventions remain critical, the screening and treatment strategy tested in JUPITER is likely to impact on new guidelines for cardiovascular disease prevention... - C-reactive protein and risk of cardiovascular disease: evidence and clinical applicationPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
Curr Atheroscler Rep 5:341-9. 2003 - Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk ScoresPaul M Ridker
Donald W Reynolds Center for Cardiovascular Research and the Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02215, USA
Circulation 109:1955-9. 2004..However, the positive predictive value of very low (<0.5 mg/L) and very high levels of hsCRP (>10.0 mg/L) is uncertain... - Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trialPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass, USA
Circulation 108:2292-7. 2003 - Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and strokePaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Ave East, Boston, Mass 02215, USA
Circulation 108:e81-5. 2003 - C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensusPaul M Ridker
Center for Cardiovascular Disease Prevention, the Division of Preventive Medicine, Brigham and Women s Hospital, The Harvard Medical School, Boston, Massachusetts 02215, USA
J Am Coll Cardiol 49:2129-38. 2007..In the meantime, however, this consensus position on hsCRP should be one to which both advocates and critics of the inflammatory hypothesis of atherosclerosis can adhere because it is one that can immediately improve patient care... - Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practicePaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
Am Heart Hosp J 2:4-9. 2004..This article provides a clinically oriented overview of appropriate settings in which to measure hsCRP, how to interpret results, and how interventions to reduce vascular risk can be targeted on the basis of hsCRP findings... - Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test?Paul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
Clin Chem 54:11-3. 2008 - Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk ScorePaul M Ridker
Donald W Reynolds Center for Cardiovascular Research and the Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA 02215, USA
JAMA 297:611-9. 2007..Despite improved understanding of atherothrombosis, cardiovascular prediction algorithms for women have largely relied on traditional risk factors... - Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trialPaul M Ridker
Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
Hypertension 48:73-9. 2006..These data raise the hypothesis that angiotensin receptor blockade may have anti-inflammatory effects in addition to blood pressure-lowering effects... - Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005Paul M Ridker
Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital, Boston, Mass 02215, USA
JAMA 295:2270-4. 2006..Whether this situation has changed over the past 5 years or whether similar effects are present among jointly funded trials is unknown... - Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive proteinPaul M Ridker
JUPITER Coordinating Center, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Am J Cardiol 100:1659-64. 2007..In conclusion, as 20 mg of rosuvastatin can reduce LDL cholesterol by up to 50%, JUPITER will also provide crucial safety data for several thousand patients who should achieve LDL cholesterol levels<50 mg/dl on a long-term basis... - Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american womenPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA, USA
Clin Chem 54:249-55. 2008..Thus, with continued follow-up of the WHS, the WGHS provides a unique scientific resource-a full-cohort, prospective, genome-wide association study among initially healthy American women... - Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevityPaul M Ridker
Harvard Medical School, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
Nutr Rev 65:S253-9. 2007..Several novel methods to reduce CRP have been proposed, including direct inhibitors as well as antisense technologies... - C-reactive protein, inflammation, and cardiovascular disease: clinical updatePaul M Ridker
Center for Cardiovascular Disease Prevention, Preventive Medicine Division, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA
Tex Heart Inst J 32:384-6. 2005 - Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in womenPaul M Ridker
Donald W Reynolds Center for Cardiovascular Research, LeDucq Center for Molecular and Genetic Epidemiology, Brigham and Women s Hospital, Boston, MA 02215, USA
JAMA 294:326-33. 2005.... - Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trialPaul M Ridker
Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
J Am Coll Cardiol 45:1644-8. 2005..The aim of this research was to compare relative efficacy of different statin regimens in achieving the dual goals of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) reduction... - Should age and time be eliminated from cardiovascular risk prediction models? Rationale for the creation of a new national risk detection programPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Ave E, Boston, MA 02215, USA
Circulation 111:657-8. 2005 - C-reactive protein levels and outcomes after statin therapyPaul M Ridker
Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
N Engl J Med 352:20-8. 2005..Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown... - Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health StudyPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Am J Hum Genet 82:1185-92. 2008.... - Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)Paul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
J Thromb Haemost 7:332-9. 2009..If successful, CIRT would both confirm the inflammatory hypothesis of atherothrombosis and open novel approaches to the treatment and prevention of cardiovascular disorders... - Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in preventionPaul M Ridker
Center for Cardiovascular Disease Prevention and the Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Circ Cardiovasc Qual Outcomes 2:616-23. 2009..However, whether the absolute risk reduction among such individuals justifies wide application of statin therapy in primary prevention is a controversial issue with broad policy and public health implications... - Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarctionPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Ave East, Boston, Mass 02215, USA
Arterioscler Thromb Vasc Biol 23:859-63. 2003..Because diabetes and atherothrombosis share common antecedents, we sought evidence that this polymorphism might also be associated with reduced risk of myocardial infarction... - A prospective study of Helicobacter pylori seropositivity and the risk for future myocardial infarction among socioeconomically similar U.S. menP M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
Ann Intern Med 135:184-8. 2001..The role of Helicobacter pylori as a determinant of cardiovascular disease is controversial... - Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)Paul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Am Heart J 162:597-605. 2011..Yet, it remains unknown whether direct inhibition of inflammation will reduce cardiovascular event rates... - HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trialPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Lancet 376:333-9. 2010..We addressed, using the JUPITER trial cohort, whether this association remains when LDL-cholesterol concentrations are reduced to the very low ranges with high-dose statin treatment... - C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American womenPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, Mass 02215, USA
Circulation 107:391-7. 2003..All of these attributes, however, are associated with increased levels of C-reactive protein (CRP)... - Clinical application of C-reactive protein for cardiovascular disease detection and preventionPaul M Ridker
Center for Cardiovascular Disease Prevention and the Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02215, USA
Circulation 107:363-9. 2003 - Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary eventsPaul M Ridker
Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02215, USA
Circulation 105:1776-9. 2002..Elevated homocysteine levels are associated with increased coronary risk, and it has been suggested that homocysteine screening may provide a method to identify high-risk patients for aggressive primary prevention... - A tale of three labels: translating the JUPITER trial data into regulatory claimsPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Clin Trials 8:417-22. 2011.... - Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating RosuvasPaul M Ridker
Center for Cardiovascular Disease Prevention and Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Circ Cardiovasc Qual Outcomes 3:447-52. 2010..However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published... - Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary preventionPaul M Ridker
Center for Cardiovascular Disease Prevention and the Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA
Circ Cardiovasc Genet 4:312-7. 2011..Hypothesis-generating data raise the possibility that carriers of the kinesin-like protein 6 (KIF6) 719 arginine (Arg) allele preferentially benefit from statin therapy, and, on this basis, a commercial assay for KIF6 has been developed... - Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary eventsP M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
N Engl J Med 344:1959-65. 2001..We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia... - Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolismPaul M Ridker
Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston 02215, USA
N Engl J Med 348:1425-34. 2003..0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio... - Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Paul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
J Am Coll Cardiol 55:1266-73. 2010..We evaluated the efficacy of statin therapy in primary prevention among individuals with moderate chronic kidney disease (CKD)... - Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)Paul M Ridker
Center for Cardiovascular Disease Prevention, Boston, Massachusetts, USA
Am J Cardiol 106:204-9. 2010..In conclusion, as the absolute risk increased with increasing hs-CRP, the absolute risk reduction associated with rosuvastatin within JUPITER was also greatest among those with the greatest entry hs-CRP levels... - Connecting the role of C-reactive protein and statins in cardiovascular diseasePaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cardiol 26:III39-44. 2003..Confirmation of these preliminary findings, if incorporated into evidence-based guidelines, may profoundly change the approach to diagnosis and treatment of CVD... - Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy menP M Ridker
Center for Cardiovascular Disease Prevention and the Divisions of Preventive Medicine, Cardiovascular Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 101:1767-72. 2000..Interleukin-6 (IL-6) plays a central role in inflammation and tissue injury. However, epidemiological data evaluating the role of IL-6 in atherogenesis are sparse... - Soluble P-selectin and the risk of future cardiovascular eventsP M Ridker
Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Circulation 103:491-5. 2001..However, little clinical data are available evaluating the role of soluble P-selectin in determining vascular risk... - Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemiaP M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 103:1191-3. 2001..However, the generalizability, speed of onset, and dose-response characteristics of this effect are uncertain... - High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular diseaseP M Ridker
Center for Cardiovascular Disease Prevention, Divisions of Cardiovascular Diseases and Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02214, USA
Circulation 103:1813-8. 2001.... - Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial diseaseP M Ridker
Brigham and Women s Hospital, 900 Commonwealth Ave E, Boston, MA 02215, USA
JAMA 285:2481-5. 2001..Several novel risk factors for atherosclerosis have recently been proposed, but few comparative data exist to guide clinical use of these emerging biomarkers... - Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular eventsPaul M Ridker
Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston 02215, USA
N Engl J Med 347:1557-65. 2002..Both C-reactive protein and low-density lipoprotein (LDL) cholesterol levels are elevated in persons at risk for cardiovascular events. However, population-based data directly comparing these two biologic markers are not available... - C-reactive protein is independently associated with fasting insulin in nondiabetic womenAruna D Pradhan
Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Ave E, Boston, Mass 02215-1204, USA
Arterioscler Thromb Vasc Biol 23:650-5. 2003..These data provide additional support for previously reported associations between subclinical inflammation and the risk of type 2 diabetes and cardiovascular disease... - A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy menSimin Liu
Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA
Atherosclerosis 166:323-9. 2003..Apolipoprotein E (apoE) plays an important role in lipid metabolism. Three common alleles in the APOE gene, E2/E3/E4, have been associated with lipoprotein disorders but their effects on myocardial infarction (MI) risk remain uncertain... - Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control studyRobert Y L Zee
Laboratory of Genetic Epidemiology, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA
Atherosclerosis 187:332-5. 2006..An exonic polymorphism (Y402H) in the complement factor H (CFH) gene, which locates within the binding sites for heparin and C-reactive protein, has recently been described and hypothesized to play an important role in atherothrombosis... - Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular diseaseHylton V Joffe
Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02215, USA
Ann Epidemiol 16:105-12. 2006..CONCLUSIONS: SHBG and total testosterone were inversely associated with CRP among HT nonusers in this study. The relationship between SHBG and CRP was more strongly inverse among leaner women... - Polymorphisms in the advanced glycosylation end product-specific receptor gene and risk of incident myocardial infarction or ischemic strokeRobert Y L Zee
Center for Cardiovascular Disease Prevention, The Donald W Reynolds Center for Cardiovascular Research, The Leducq Center for Molecular and Genetic Epidemiology, Boston, Mass, USA
Stroke 37:1686-90. 2006..However, to date, no genetic-epidemiological data are available on risk of atherothrombotic events among nondiabetic populations... - High prevalence of metabolic syndrome among young women with nonfatal myocardial infarctionLynn L Amowitz
Division of General Medicine and Women s Health, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Womens Health (Larchmt) 13:165-75; discussion 175. 2004..The aim of this study was to determine if the metabolic syndrome (MetS) or other risk factors might be common among young women with nonfatal myocardial infarction (MI)... - Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22Kausik K Ray
TIMI Study Group, Cardiovascular Division and the Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02115, USA
Arterioscler Thromb Vasc Biol 29:424-30. 2009.... - Prospective evaluation of the alcohol dehydrogenase gamma1/gamma2 gene polymorphism and risk of strokeRobert Y L Zee
Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Stroke 35:e39-42. 2004..Genetic polymorphism of the alcohol dehydrogenase type 3 gene (ADH1C) has recently been associated with reduced risk of myocardial infarction. However, data on risk of stroke are not available... - Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women's Genome Health StudyDavid Conen
Department of Medicine, Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
J Hypertens 27:476-83. 2009..The aim of the present study was to assess the association of 77 previously characterized gene variants in 52 candidate genes from various biological pathways with blood pressure (BP) progression and incident hypertension... - A randomized trial of rosuvastatin in the prevention of venous thromboembolismRobert J Glynn
Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
N Engl J Med 360:1851-61. 2009..Observational studies have yielded variable estimates of the effect of statin therapy on the risk of venous thromboembolism, and evidence from randomized trials is lacking... - A prospective evaluation of the heat shock protein 70 gene polymorphisms and the risk of strokeRobert Y L Zee
Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Thromb Haemost 87:622-5. 2002..In this large, prospective study, genetic polymorphisms in the HSP70 genes were not associated with risks of future stroke. Screening for these polymorphisms is unlikely to be a useful tool for risk assessment... - Genome-wide association study identifies variants at the IL18-BCO2 locus associated with interleukin-18 levelsMeian He
Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
Arterioscler Thromb Vasc Biol 30:885-90. 2010..We sought to identify the common genetic variants associated with IL-18 levels... - Risk factors for progression of peripheral arterial disease in large and small vesselsVictor Aboyans
Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA 92093 0607, USA
Circulation 113:2623-9. 2006..Using noninvasive tests, we assessed the role of traditional and novel risk factors on PAD progression. We hypothesized that the risk factors for large-vessel PAD (LV-PAD) progression might differ from small-vessel PAD (SV-PAD)... - Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in menAruna D Pradhan
Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02115-1204, USA
Circulation 106:820-5. 2002..CONCLUSIONS: Elevated levels of sICAM-1 are independently associated with the development of accelerated atherosclerosis among otherwise healthy men even in the absence of acute coronary occlusion... - Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case-control evaluationRobert Y L Zee
Laboratory of Genetic and Molecular Epidemiology, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, Massachusetts 02215, USA
Stroke 37:2012-7. 2006..Case-control studies in other populations have yielded mixed evidence for association. A recent analysis in a prospective, non-Icelandic study found an association with stroke after stratification by hypertension... - Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trialPaul M Ridker
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Lancet 373:1175-82. 2009..8 mmol/L (<70 mg/dL). However, the benefit of lowering both LDL cholesterol and hsCRP after the start of statin therapy is controversial. We prospectively tested this hypothesis... - Interaction between inflammation-related gene polymorphisms and cigarette smoking on the risk of myocardial infarction in the Physician's Health StudySarah A Rosner
Department of Epidemiology, Harvard School of Public Health Kresge 911, 677 Huntington Avenue, Boston, MA 02115, USA
Hum Genet 118:287-94. 2005..However, these results should be interpreted with caution due to the potential for false positive results that can arise from analyses with multiple comparisons... - Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged womenSimin Liu
Center of Cardiovascular Prevention, the Division of Preventive Medicine, Harvard Medical School, Boston 02215, USA
Am J Clin Nutr 75:492-8. 2002..Recent prospective data suggest that intake of rapidly digested and absorbed carbohydrates with a high dietary glycemic load is associated with an increased risk of ischemic heart disease... - Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolismRobert Y L Zee
Laboratory of Genetic and Molecular Epidemiology, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medial School, 900 CommonwealthAvenue East, Boston, MA 02215, USA
Atherosclerosis 197:694-9. 2008..The present investigation provides evidence for an association of the P2RY12 haplotype H2 with lower risk of DVT/PE; however these findings require replication in other well-designed studies... - Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health StudyRobert J Glynn
Division of Preventive Medicine, Brigham and Women s Hospital, 900 Commonwealth Ave E, Boston, MA 02215 1204, USA
Circulation 116:1497-503. 2007..Supplementation with vitamin E may antagonize vitamin K in healthy adults, but it is unclear whether intake of vitamin E decreases the risk of venous thromboembolism (VTE)... - A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in womenPaul M Ridker
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, USA
N Engl J Med 352:1293-304. 2005.... - The effect of including C-reactive protein in cardiovascular risk prediction models for womenNancy R Cook
Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
Ann Intern Med 145:21-9. 2006..While high-sensitivity C-reactive protein (hsCRP) is an independent predictor of cardiovascular risk, global risk prediction models incorporating hsCRP have not been developed for clinical use... - Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosisRobert Y L Zee
Division of Preventive Medicine, The Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215 1204, USA
Atherosclerosis 162:217-9. 2002..These data suggest that genetic and environmental determinants each importantly contribute to the vascular risk associated with inflammation... - Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trialKausik K Ray
Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
J Am Coll Cardiol 46:1417-24. 2005.... - Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U.S. womenYiqing Song
Division of Preventive Medicine, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
Diabetes Care 28:1438-44. 2005..The aim of this study was to examine whether and to what extent magnesium intake is related to systemic inflammation and the metabolic syndrome... - Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER StudyRobert J Glynn
Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Clin Chem 55:305-12. 2009..Although studies of specific populations have suggested that hsCRP is a reliable longitudinal marker, it is unclear how strongly hsCRP tracks in individuals after a single increased concentration... - Tryptophanyl-tRNA synthetase gene polymorphisms and risk of incident myocardial infarctionRobert Y L Zee
Center for Cardiovascular Disease Prevention, The LeDucq Center for Cardiovascular Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
Atherosclerosis 181:137-41. 2005..In conclusion, we found no evidence for an association between the common polymorphisms or haplotypes of the tryptophanyl-tRNA synthetase gene tested and risk of myocardial infarction... - A prospective evaluation of the CD14 and CD18 gene polymorphisms and risk of strokeRobert Y L Zee
Center for Cardiovascular Disease Prevention, the Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02215, USA
Stroke 33:892-5. 2002.... - Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal womenMelissa E Weinberg
Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
Metabolism 55:1473-80. 2006..7 kg/m2. An androgenic hormone profile is associated with both the individual components of the metabolic syndrome and clustering of metabolic abnormalities in postmenopausal women... - Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational StudyRobert D Langer
Department of Family and Preventive Medicine, University of California, San Diego, 9500 Gilman Drive, MC 0978, La Jolla, CA 92093 0978, USA
Thromb Haemost 93:1108-16. 2005..Some associations differed between women with and without incident CHD, especially for EP, where inflammatory and thrombotic markers were higher in cases. These associations remain speculative pending confirmation in randomized trials... - Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrumPaul M Ridker
Circulation 105:2583-5. 2002 - High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in womenDebra A Schaumberg
Division of Preventive Medicine, 900 Commonwealth Ave E, Boston, MA 02215, USA
Arch Ophthalmol 125:300-5. 2007..To investigate whether high-sensitivity C-reactive protein (hsCRP) and other biomarkers of inflammation predict age-related macular degeneration (AMD)... - C-reactive protein gene variation and type 2 diabetes mellitus: a case-control studyRobert Y L Zee
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital and Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA
Atherosclerosis 197:931-6. 2008..C-reactive protein (CRP) gene variation, in particular an rs2794521 variant was recently associated with type 2 diabetes mellitus (T2DM) in Pima Indians... - Association of renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort studyDavid Conen
Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
J Hypertens 26:1780-6. 2008..The aim of the present study was to assess the relationship of six previously characterized gene variants in the renin-angiotensin system and the NOS3 gene with blood pressure progression and incident hypertension... - Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of womenYiqing Song
Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Diabetes 56:1898-904. 2007..S. postmenopausal women, implicating an etiological role of endothelial dysfunction in the pathogenesis of type 2 diabetes... - Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysisDaniel I Chasman
Donald W Reynolds Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, Massachusetts, United States of America
PLoS Genet 5:e1000730. 2009.... - Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational studyAruna D Pradhan
Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215-1204, USA
JAMA 288:980-7. 2002..However, use or nonuse of HRT had less importance as a predictor of cardiovascular risk than did baseline levels of either CRP or IL-6... - Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in womenGavin J Blake
Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02215, USA
Circulation 106:1930-7. 2002..However, the magnitude of predictive value of LDL particle concentration (NMR) was not substantively different from that of the total cholesterol to HDL cholesterol ratio and was less than that of C-reactive protein... - Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patientsTareq S Harb
Cardiology Unit, Department of Medicine, University of Rochester Medical Center, New York 14642, USA
Am J Cardiol 91:1120-3. 2003 - Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?Samia Mora
Center for Cardiovascular Disease Prevention and Division of Cardiovascular Disease, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
Am J Cardiol 97:33A-41A. 2006..Ongoing work will determine whether hs-CRP reduction, independent of LDL cholesterol reduction, results in a net clinical benefit... - Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in womenAruna D Pradhan
Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA
Am J Med 114:438-44. 2003..To assess the associations among baseline levels of fasting insulin and proinsulin, proinsulin:insulin ratio, and the development of type 2 diabetes mellitus in apparently healthy middle-aged women... - Inflammatory and thrombotic blood markers and walking-related disability in men and women with and without peripheral arterial diseaseMary M McDermott
Feinberg School of Medicine, Northwestern University, 675 N St Clair, Chicago, IL 60611, USA
J Am Geriatr Soc 52:1888-94. 2004..To determine whether higher circulating levels of thrombotic and inflammatory markers are associated with greater disability... - Genetic variants of tumor necrosis factor superfamily, member 4 (TNFSF4), and risk of incident atherothrombosis and venous thromboembolismAnders Malarstig
Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Clin Chem 54:833-40. 2008..Recent data have implicated tumor necrosis factor (ligand) superfamily, member 4 (TNFSF4) gene variation in myocardial infarction in women; however, no prospective data are available on either incident arterial or venous disorders... - Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial indexMary M McDermott
Feinberg School of Medicine, Northwestern University, 675 N St Clair, Chicago, IL 60611, USA
Am J Cardiol 92:194-9. 2003..We conclude that D-dimer levels may be more sensitive than other blood markers for measuring the extent of atherosclerosis in lower extremity arteries... - Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology?Andrew D Blann
Stroke 33:2141-3. 2002
Research Grants
- Training Program in the Epidemiology of CVDPaul Ridker; Fiscal Year: 2007..end of abstract) ..
- THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMENPaul Ridker; Fiscal Year: 2002....
- SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSISPaul Ridker; Fiscal Year: 2002....